Supply Chain Intelligence

LENZ Therapeutics, Inc. Supply Chain

LENZ supply chain intelligence for LENZ Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

LENZ ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

4Suppliers
15Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

LENZ Therapeutics, Inc. (LENZ) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships
4Distinct source URLs
6High confidence
0.730Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

LENZ Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
ALVO Alvotech 72% Item 1. Business Overview We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. On July 31, 2025, the United States (“…
ALVO Alvotech 72% Reciprocal relationship from ALVO graph: Reciprocal relationship from LENZ graph: Item 1. Business Overview We are a commercial pharmaceutical company focused on the development and commercialization…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from LENZ graph: Good Manufacturing Practices (“cGMP”) regulatory guidelines. A Drug Master File (“DMF”) is on file with the FDA for th…
JNJ Johnson & Johnson 72% Good Manufacturing Practices (“cGMP”) regulatory guidelines. A Drug Master File (“DMF”) is on file with the FDA for the API. Commercial supply agreements have been secured with our API suppliers with…

LENZ Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
LUNATUS LUNATUS 92% In January 2026, LENZ announced an exclusive commercialization partnership with Lunatus for the Middle East.
WHOLESALER-CUSTOMERS WHOLESALER-CUSTOMERS 92% For the three months ended March 31, 2026, the Company's three wholesaler customers each individually accounted for more than 10% of total product sales.
ALVO Alvotech 72% Item 1. Business Overview We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. On July 31, 2025, the United States (“…
ALVO Alvotech 72% Reciprocal relationship from ALVO graph: Reciprocal relationship from LENZ graph: Reciprocal relationship from ALVO graph: Reciprocal relationship from LENZ graph: Reciprocal relationship from ALVO g…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from LENZ graph: y as described in “Consumer Sampling Strategy”. To meet the long-term usage needs of young and old presbyopes, we plan…
JNJ Johnson & Johnson 72% y as described in “Consumer Sampling Strategy”. To meet the long-term usage needs of young and old presbyopes, we plan to offer both retail access and collaborate with e-pharmacy vendors to provide e…
GENERATE-MERGER-SUB-INC GENERATE-MERGER-SUB-INC 62% ware on October 28, 2020 upon the filing of a Certificate of Conversion to convert Presbyopia Therapies, LLC, a Delaware limited liability company (formed in September 2013), to a Delaware corporatio…
JI-XING-PHARMACEUTICALS-HONG-KONG-LIMITED JI-XING-PHARMACEUTICALS-HONG-KONG-LIMITED 62% elective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle resulting in a pinhole effect and uniquely achieves a sub-2mm pupil tha…
LENZ-THERAPEUTICS-OPERATIONS-INC LENZ-THERAPEUTICS-OPERATIONS-INC 62% orporated in Ontario, Canada in June 2017 as Longbow Therapeutics Inc., and was reincorporated in the State of Delaware in October 2019. The Company has a wholly owned subsidiary, LENZ Therapeutics O…
LICENSE-PARTNERS LICENSE-PARTNERS 62% us in other jurisdictions, and could result in administrative or judicially imposed sanctions, including warning letters, civil and criminal penalties, injunctions, product seizures or detention, pro…
LONGBOW-THERAPEUTICS-INC LONGBOW-THERAPEUTICS-INC 62% orporated in Ontario, Canada in June 2017 as Longbow Therapeutics Inc., and was reincorporated in the State of Delaware in October 2019. The Company has a wholly owned subsidiary, LENZ Therapeutics O…
LOTUS-PHARMACEUTICAL-CO LOTUS-PHARMACEUTICAL-CO 62% elective miotic that interacts with the iris, with minimal ciliary muscle stimulation. VIZZ contracts the iris sphincter muscle resulting in a pinhole effect and uniquely achieves a sub-2mm pupil tha…
LOTUS-PHARMACEUTICAL-CO-LTD LOTUS-PHARMACEUTICAL-CO-LTD 62% not being properly identified; • clinical supplies not being delivered to clinical sites on time for any future clinical trials we conduct, leading to clinical trial interruptions, or drug supplies n…
PRESBYOPIA-THERAPIES-LLC PRESBYOPIA-THERAPIES-LLC 62% ware on October 28, 2020 upon the filing of a Certificate of Conversion to convert Presbyopia Therapies, LLC, a Delaware limited liability company (formed in September 2013), to a Delaware corporatio…
USA-LLC USA-LLC 62% ed on our unaudited condensed consolidated financial statements and related notes thereto, which we have prepared in accordance 23 Table of Contents with U.S. GAAP. You should read the discussion and…

LENZ Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
LENZ-DEBT-10655 Xbrl Convertible 90% xbrl convertible detail from xbrl 2024-12-31.
LENZ-DEBT Debt stack $673,000 90% Market cache reports total debt of $673,000.
LENZ-DEBT-10654 Warrants outstanding: 1918000 90% xbrl warrant detail from xbrl 2025-12-31.

LENZ Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for LENZ Therapeutics, Inc..

LENZ Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
LENZ-OWNER-RA-CAPITAL-MANAGEMENT-L-P RA CAPITAL MANAGEMENT, L.P. 90% 13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 148 tracked holders.

LENZ Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ADGM Adagio Medical Holdings, Inc. 100.00 2
ATON AlphaTON Capital Corp 100.00 2
ATRA Atara Biotherapeutics, Inc. 100.00 2
BCAX Bicara Therapeutics Inc. 100.00 2
ABBV AbbVie Inc. 100.00 2
AURA Aura Biosciences, Inc. 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CLGN CollPlant Biotechnologies Ltd. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
ALVO Alvotech 100.00 1 ['customer', 'supplier']
AORT Artivion, Inc. 100.00 2
ACIU AC Immune SA 100.00 2
CSTE Caesarstone Ltd. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
SNNUF Smith & Nephew plc 100.00 2
ALC Alcon Inc. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
FDMT 4D Molecular Therapeutics, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for LENZ Therapeutics, Inc..

Unlock full LENZ data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
LENZ
Unlock LENZ Supply Chain Data
Verified relationships include:
ALVOAlvotechSupplier72%
ALVOAlvotechSupplier72%
LUNATUSLUNATUSCustomer92%
WHOLESALER-CUSTOMERSWHOLESALER-CUSTOMERSCustomer92%
+19 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →